US$3 billion and €4.25 billion of notes priced
Boston Scientific has priced US$3 billion and €4.25 billion of senior notes to help fund its proposed acquisition of Penumbra. The debt carries a range of maturities and includes special redemption terms if the transaction fails to close.
- US$3 billion across four senior note tranches
- €4.25 billion across six euro-denominated tranches
- Proceeds earmarked primarily for the Penumbra acquisition
- Euro notes fully and unconditionally guaranteed by Boston Scientific
- Special redemption at 101% if the deal is abandoned or misses its deadline
Add us as a preferred source on Google
Boston Scientific Corporation (NYSE:BSX) is lining up a substantial multi-currency debt package for its proposed acquisition of Penumbra, pricing US$3 billion of dollar-denominated senior notes alongside €4.25 billion of euro notes. The offerings are expected to close on 1 December 2026, subject to customary conditions, and are intended to fund the cash component of the transaction as well as related costs.
Bottom Line?
The financing plan gives Boston Scientific a clearer path to the Penumbra deal, but the next test is how the added debt and currency exposure sit alongside the acquisition once both transactions close.
Questions in the middle?
- Will the Penumbra acquisition complete by the applicable outside date, or will the special mandatory redemption provisions be triggered?
- What will Boston Scientific's leverage and liquidity look like after the debt is issued and the acquisition is funded?
- How will the company manage the longer-dated euro debt, including the floating-rate tranche and currency exposure?
Sources
1-
Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation; Other Events (opens in a new tab)Official market announcement. SEC filing · Boston Scientific Corporation · 20 Nov 2026 · sec.gov